Clinical trial

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

NCT04253964

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2020-07-01

PhasePHASE2

Study timeline

Study start (actual)2020-07-01Date precision: day

Registry last updated2026-09-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Nonsmall Cell Lung Cancerunresolved

Performance Statusunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Cemiplimab-RwlcDRUG · verified · RxNorm: cemiplimab-rwlc

CarboplatinDRUG · verified · RxNorm: carboplatin

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Nab paclitaxelDRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

CisplatinDRUG · verified · RxNorm: cisplatin

Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)OTHER

QLQ-C30 Global Health/Quality of Life QuestionnaireOTHER

COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported OutcomesOTHER

PROMIS and FACT-G QuestionnairesOTHER

Sleep Disorder Assessments (ISI, Berlin Sleep Questionnaire)OTHER

Sponsors & collaborators

Wake Forest University Health Scienceslead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

CharlotteNorth Carolina, United States1 Winston-SalemNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04253964 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.